| Entry |
|
|---|
| Name |
Viltolarsen (JAN/USAN);
Viltepso (TN) |
|---|
| Product |
|
|---|
| Formula |
C244H381N113O88P20
|
|---|
| Exact mass |
6921.3564
|
|---|
| Mol weight |
6924.8155
|
|---|
| Remark |
| Therapeutic category: | 1900 |
|
|---|
| Efficacy |
Translation inhibitor |
|---|
| Disease |
Duchenne muscular dystrophy (amenable to exon 53 skipping mutated) [DS: H01963] |
|---|
| Comment |
Antisense oligonucleotide
Treatment of Duchenne muscular dystrophy
|
|---|
| Target |
|
|---|
| Brite |
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Viltolarsen
D11528 Viltolarsen (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
19 Other agents affecting nervous system and sensory organs
190 Other agents affecting nervous system and sensory organs
1900 Other agents affecting nervous system and sensory organs
D11528 Viltolarsen (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Cellular process
Cytoskeleton
DMD* [HSA_VAR:1756v1]
D11528 Viltolarsen (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11528
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11528
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11528
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D11528
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
